tradingkey.logo

Royalty Pharma Acquires Royalty Interest In Nuvalent’S Neladalkib And Zidesamtinib For Up To $315 Million

ReutersDec 16, 2025 12:18 PM

- Royalty Pharma PLC RPRX.O:

  • ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN NUVALENT’S NELADALKIB AND ZIDESAMTINIB FOR UP TO $315 MILLION

  • ROYALTY PHARMA - ROYALTY DURATION FOR BOTH THERAPIES EXTENDS THROUGH 2041 TO 2042

  • ROYALTY PHARMA - BUYS LOW-SINGLE DIGIT ROYALTY ON NELADALKIB AND ZIDESAMTINIB

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI